Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haematological and Biochemical Effects of Sofosbuvir and Daclatasvir in HCV
NCT03163849Phase 3Unknown
- Sponsor
- Assiut University
- Start
- Sep 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sofosbuvir and daclatasvir in hepatitis C (HCV) (2 arms), sponsored by Assiut University. Primary endpoints: Percentage of patients with hematological changes at 12 weeks and Percentage of patients with antibodies against RBCs. Status: unknown.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03163849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163849.